Teligent Company Profile (NASDAQ:TLGT)

About Teligent (NASDAQ:TLGT)

Teligent logoTeligent, Inc. is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 34 Abbreviated New Drug Application(ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2016.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TLGT
  • CUSIP: N/A
  • Web: www.teligent.com
Capitalization:
  • Market Cap: $366.27 million
  • Outstanding Shares: 53,391,000
Average Prices:
  • 50 Day Moving Avg: $6.87
  • 200 Day Moving Avg: $6.87
  • 52 Week Range: $5.75 - $7.99
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 21.44
  • P/E Growth: 6.44
Sales & Book Value:
  • Annual Revenue: $72.39 million
  • Price / Sales: 5.06
  • Book Value: $1.09 per share
  • Price / Book: 6.29
Profitability:
  • EBIDTA: $6.48 million
  • Net Margins: -11.36%
  • Return on Equity: 1.49%
  • Return on Assets: 0.46%
Debt:
  • Debt-to-Equity Ratio: 1.99%
  • Current Ratio: 4.37%
  • Quick Ratio: 3.71%
Misc:
  • Average Volume: 488,057 shs.
  • Beta: 1.6
  • Short Ratio: 22.73
 

Frequently Asked Questions for Teligent (NASDAQ:TLGT)

What is Teligent's stock symbol?

Teligent trades on the NASDAQ under the ticker symbol "TLGT."

How were Teligent's earnings last quarter?

Teligent, Inc. (NASDAQ:TLGT) released its earnings results on Tuesday, August, 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.02 by $0.04. The business earned $18.40 million during the quarter, compared to analyst estimates of $20.11 million. Teligent had a negative net margin of 11.36% and a positive return on equity of 1.49%. The business's quarterly revenue was up 7.4% compared to the same quarter last year. During the same period last year, the business earned $0.02 EPS. View Teligent's Earnings History.

Where is Teligent's stock going? Where will Teligent's stock price be in 2017?

3 brokers have issued 12 month price targets for Teligent's stock. Their forecasts range from $8.00 to $11.00. On average, they expect Teligent's stock price to reach $9.33 in the next year. View Analyst Ratings for Teligent.

What are analysts saying about Teligent stock?

Here are some recent quotes from research analysts about Teligent stock:

  • 1. Canaccord Genuity analysts commented, "We’re confident that the company’s revised expectations are achievable and delays at the agency will resolve in short order. We continue to view Teligent as a uniquely positioned generic company poised for meaningful growth over the next several years. We maintain our BUY rating and $11 price target on TLGT shares. Light revenue due to lidocaine ointment and Zantac; lidocaine solution a surprising star in the report. Teligent’s 2Q/17 revenue was $18.4 mm compared to our $19mm estimate and $20.3 mm consensus. In our post-launch thoughts, we believed investors were expecting a light quarter and potential downward revision to 2H/17 expectations. Adjusted loss per share was ($0.01) compared to our EPS estimate of +$0.01 and consensus of +$0.02. Teligent saw incremental competition and double-digit price erosion on lidocaine ointment and a return of a competitor on Zantac injection coupled with lower-than-expected Zantac utilization rates due to recent inventory shortages that changed physician use patterns." (8/8/2017)
  • 2. According to Zacks Investment Research, "Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. " (7/6/2017)

Who are some of Teligent's key competitors?

Who are Teligent's key executives?

Teligent's management team includes the folowing people:

  • Jason Grenfell-Gardner, President, Chief Executive Officer, Director
  • Jenniffer L. Collins, Chief Financial Officer
  • Stephen Richardson, Chief Scientific Officer
  • Carole S. Ben-Maimon M.D., Director
  • John E. Celentano, Director
  • Steven Hubrig Koehler, Director
  • Narendra N. Borkar, Independent Director
  • Bhaskar Michael Chaudhuri Ph.D., Independent Director

Who owns Teligent stock?

Teligent's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (10.53%), Pembroke Management LTD (4.25%), Vanguard Group Inc. (3.85%), Elk Creek Partners LLC (3.18%), Broadfin Capital LLC (2.75%) and AMI Asset Management Corp (2.66%). Company insiders that own Teligent stock include James C Gale and Jason Grenfell-Gardner. View Institutional Ownership Trends for Teligent.

Who sold Teligent stock? Who is selling Teligent stock?

Teligent's stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Elk Creek Partners LLC, Broadfin Capital LLC, Pembroke Management LTD, Summit Creek Advisors LLC, Suffolk Capital Management LLC, Kopp Investment Advisors LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Teligent.

Who bought Teligent stock? Who is buying Teligent stock?

Teligent's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Stifel Financial Corp, FMR LLC, Russell Investments Group Ltd., RK Capital Management LLC, Argent Capital Management LLC, Timpani Capital Management LLC and State Street Corp. Company insiders that have bought Teligent stock in the last two years include James C Gale and Jason Grenfell-Gardner. View Insider Buying and Selling for Teligent.

How do I buy Teligent stock?

Shares of Teligent can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Teligent's stock price today?

One share of Teligent stock can currently be purchased for approximately $6.86.


MarketBeat Community Rating for Teligent (NASDAQ TLGT)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  85 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  179
MarketBeat's community ratings are surveys of what our community members think about Teligent and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Teligent (NASDAQ:TLGT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $9.33 (36.05% upside)

Analysts' Ratings History for Teligent (NASDAQ:TLGT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/23/2017Roth CapitalSet Price TargetBuy$9.00LowView Rating Details
8/14/2017Deutsche Bank AGLower Price TargetHold$9.00 -> $8.00LowView Rating Details
8/8/2017Canaccord GenuityReiterated RatingBuy$11.00HighView Rating Details
6/29/2016JMP SecuritiesInitiated CoverageHoldN/AView Rating Details
6/22/2016Raymond James Financial, Inc.Initiated CoverageStrong-Buy$11.00N/AView Rating Details
4/26/2016Oppenheimer Holdings, Inc.Reiterated RatingHoldN/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for Teligent (NASDAQ:TLGT)
Earnings by Quarter for Teligent (NASDAQ:TLGT)
Earnings History by Quarter for Teligent (NASDAQ TLGT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017$0.02($0.02)$20.11 million$18.40 millionViewListenView Earnings Details
3/7/2017Q4 2016$0.01$17.97 million$17.90 millionViewListenView Earnings Details
10/27/2016Q3$0.00$0.01$16.90 million$16.20 millionViewListenView Earnings Details
7/28/2016Q2($0.02)$0.02$16.03 million$17.14 millionViewListenView Earnings Details
4/28/2016Q116($0.03)$0.02$14.33 million$15.70 millionViewN/AView Earnings Details
3/9/2016Q415($0.02)($0.02)$11.69 million$13.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Teligent (NASDAQ:TLGT)
2017 EPS Consensus Estimate: $0.14
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.03$0.03$0.03
Q2 20171$0.02$0.02$0.02
Q3 20171$0.04$0.04$0.04
Q4 20171$0.05$0.05$0.05
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Teligent (NASDAQ:TLGT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Teligent (NASDAQ:TLGT)
Insider Ownership Percentage: 22.60%
Institutional Ownership Percentage: 65.96%
Insider Trades by Quarter for Teligent (NASDAQ:TLGT)
Institutional Ownership by Quarter for Teligent (NASDAQ:TLGT)
Insider Trades by Quarter for Teligent (NASDAQ:TLGT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/11/2016James C GaleDirectorBuy15,000$4.91$73,650.00View SEC Filing  
3/11/2016Jason Grenfell-GardnerCEOBuy10,500$4.82$50,610.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Teligent (NASDAQ:TLGT)
Latest Headlines for Teligent (NASDAQ:TLGT)
Source:
DateHeadline
americanbankingnews.com logoAMAG Pharmaceuticals (AMAG) vs. Teligent (TLGT) Financial Contrast
www.americanbankingnews.com - September 24 at 10:08 PM
americanbankingnews.com logoComparing Teligent (TLGT) & Its Competitors
www.americanbankingnews.com - September 21 at 6:26 AM
streetinsider.com logoTeligent (TLGT) Granted FDA Approval of Triamcinolone Acetonide Cream USP, 0.1%
www.streetinsider.com - September 20 at 10:03 AM
finance.yahoo.com logoTeligent, Inc. Announces FDA Approval of Triamcinolone Acetonide Cream USP, 0.1%
finance.yahoo.com - September 19 at 8:34 AM
americanbankingnews.com logoTeligent, Inc. (TLGT) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 19 at 2:38 AM
feeds.benzinga.com logoTeligent, Inc. Appoints Thomas J. Sabatino, Jr. to Board of Directors
feeds.benzinga.com - September 18 at 6:24 PM
americanbankingnews.com logo$19.17 Million in Sales Expected for Teligent, Inc. (TLGT) This Quarter
www.americanbankingnews.com - September 18 at 1:40 PM
finance.yahoo.com logoTeligent, Inc. to Present at Morgan Stanley 15th Annual Global Healthcare Conference on September 12, 2017
finance.yahoo.com - September 12 at 11:00 AM
americanbankingnews.com logoTeligent, Inc. (TLGT) Expected to Post Quarterly Sales of $19.17 Million
www.americanbankingnews.com - August 30 at 11:00 AM
americanbankingnews.com logoTeligent, Inc. (TLGT) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - August 25 at 2:38 AM
americanbankingnews.com logoRoth Capital Analysts Give Teligent, Inc. (TLGT) a $9.00 Price Target
www.americanbankingnews.com - August 24 at 6:28 PM
finance.yahoo.com logoETFs with exposure to Teligent, Inc. : August 23, 2017
finance.yahoo.com - August 24 at 2:44 PM
streetinsider.com logoTeligent (TLGT) Reports FDA Approval of Clobetasol Propionate Cream USP, 0.05%, Emollient
www.streetinsider.com - August 23 at 12:38 PM
finance.yahoo.com logoTeligent, Inc. Announces FDA Approval of Clobetasol Propionate Cream USP, 0.05%, Emollient
finance.yahoo.com - August 23 at 12:38 PM
americanbankingnews.com logoTeligent, Inc. (NASDAQ:TLGT) Price Target Cut to $8.00 by Analysts at Deutsche Bank AG
www.americanbankingnews.com - August 14 at 11:34 AM
americanbankingnews.com logoAegerion Pharmaceuticals (AEGR) & Teligent (NASDAQ:TLGT) Financial Review
www.americanbankingnews.com - August 13 at 10:30 PM
finance.yahoo.com logoTeligent, Inc. :TLGT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017
finance.yahoo.com - August 10 at 4:38 PM
americanbankingnews.com logo$0.04 Earnings Per Share Expected for Teligent, Inc. (TLGT) This Quarter
www.americanbankingnews.com - August 10 at 9:52 AM
seekingalpha.com logoTeligent's (TLGT) CEO Jason Grenfell-Gardner on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 9 at 8:17 AM
finance.yahoo.com logoTeligent, Inc. Announces Second Quarter 2017 Results
finance.yahoo.com - August 9 at 8:17 AM
finance.yahoo.com logoTeligent reports 2Q loss
finance.yahoo.com - August 9 at 8:16 AM
finance.yahoo.com logoEdited Transcript of TLGT earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 8:16 AM
americanbankingnews.com logoTeligent, Inc. (NASDAQ:TLGT) Given Buy Rating at Canaccord Genuity
www.americanbankingnews.com - August 8 at 10:14 PM
americanbankingnews.com logoTeligent, Inc. (NASDAQ:TLGT) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - August 8 at 9:30 PM
finance.yahoo.com logoTeva shares plummeted 24% on cheaper generic drug prices, pulling rivals lower
finance.yahoo.com - August 4 at 9:03 AM
finance.yahoo.com logoTeligent, Inc. – Value Analysis (NASDAQ:TLGT) : July 31, 2017
finance.yahoo.com - August 1 at 6:55 AM
americanbankingnews.com logoTeligent, Inc. (NASDAQ:TLGT) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 31 at 8:57 AM
finance.yahoo.com logoTeligent, Inc. to Hold Conference Call for Second Quarter 2017 Results
finance.yahoo.com - July 28 at 8:51 AM
americanbankingnews.com logoValuEngine Downgrades Teligent, Inc. (NASDAQ:TLGT) to Sell
www.americanbankingnews.com - July 26 at 12:09 AM
americanbankingnews.com logoTeligent Inc (TLGT) Lowered to Sell at BidaskClub
www.americanbankingnews.com - July 24 at 7:52 PM
streetinsider.com logoTeligent (TLGT) Receives FDA Approval for Erythromycin Topical Gel USP, 2%
www.streetinsider.com - July 22 at 9:39 AM
finance.yahoo.com logoTeligent, Inc. Announces FDA Approval Of Erythromycin Topical Gel USP, 2%
finance.yahoo.com - July 22 at 9:39 AM
finance.yahoo.com logoTeligent Shares Rise on FDA Approval for Erythromycin Topical Gel
finance.yahoo.com - July 22 at 9:39 AM
americanbankingnews.com logoZacks: Analysts Expect Teligent, Inc. (NASDAQ:TLGT) Will Post Quarterly Sales of $20.20 Million
www.americanbankingnews.com - July 22 at 8:24 AM
americanbankingnews.com logo Analysts Expect Teligent, Inc. (TLGT) to Post $0.03 Earnings Per Share
www.americanbankingnews.com - July 20 at 10:15 PM
americanbankingnews.com logoTeligent, Inc. (TLGT) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 19 at 8:53 AM
finance.yahoo.com logoTeligent, Inc. breached its 50 day moving average in a Bullish Manner : TLGT-US : July 17, 2017
finance.yahoo.com - July 18 at 9:04 AM
americanbankingnews.com logoDeutsche Bank AG Increases Teligent, Inc. (NASDAQ:TLGT) Price Target to $9.00
www.americanbankingnews.com - July 17 at 5:58 PM
americanbankingnews.com logoCollegium Pharmaceutical (COLL) vs. Teligent (TLGT) Critical Review
www.americanbankingnews.com - July 14 at 10:29 PM
finance.yahoo.com logoETFs with exposure to Teligent, Inc. : July 11, 2017
finance.yahoo.com - July 12 at 8:11 AM
americanbankingnews.com logoTeligent, Inc. (TLGT) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - July 6 at 2:00 PM
americanbankingnews.com logoTeligent, Inc. (TLGT) Expected to Announce Quarterly Sales of $20.70 Million
www.americanbankingnews.com - June 28 at 10:12 AM
americanbankingnews.com logo Analysts Expect Teligent, Inc. (TLGT) to Announce $0.03 EPS
www.americanbankingnews.com - June 26 at 8:38 PM
finance.yahoo.com logoETFs with exposure to Teligent, Inc. : June 14, 2017
finance.yahoo.com - June 15 at 2:23 AM
americanbankingnews.com logoAnalyzing Lannett Co (LCI) and Teligent (TLGT)
www.americanbankingnews.com - June 12 at 12:06 AM
americanbankingnews.com logoHead to Head Comparison: Teligent (TLGT) & Theravance Biopharma (TBPH)
www.americanbankingnews.com - June 9 at 7:43 AM
americanbankingnews.com logo Brokerages Expect Teligent Inc (TLGT) Will Post Quarterly Sales of $20.70 Million
www.americanbankingnews.com - June 2 at 1:10 PM
finance.yahoo.com logoETFs with exposure to Teligent, Inc. : May 31, 2017
finance.yahoo.com - May 31 at 10:12 PM
americanbankingnews.com logo Brokerages Expect Teligent Inc (TLGT) Will Post Earnings of $0.03 Per Share
www.americanbankingnews.com - May 31 at 4:22 PM
seekingalpha.com logoTeligent (TLGT) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow
seekingalpha.com - May 24 at 8:50 AM

Social

Chart

Teligent (TLGT) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff